Blue Trust Inc. Boosts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Blue Trust Inc. lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 37.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,118 shares of the medical equipment provider’s stock after acquiring an additional 1,923 shares during the quarter. Blue Trust Inc.’s holdings in Hologic were worth $528,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Wolff Wiese Magana LLC bought a new stake in shares of Hologic during the third quarter valued at approximately $25,000. Innealta Capital LLC purchased a new position in Hologic during the 2nd quarter valued at about $25,000. iA Global Asset Management Inc. bought a new stake in shares of Hologic in the 1st quarter valued at about $37,000. Sunbelt Securities Inc. bought a new position in shares of Hologic during the second quarter valued at approximately $37,000. Finally, Cranbrook Wealth Management LLC bought a new position in shares of Hologic during the second quarter valued at approximately $47,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

Shares of HOLX stock opened at $81.58 on Wednesday. The firm’s 50-day moving average is $80.92 and its two-hundred day moving average is $77.77. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The company has a market capitalization of $19.04 billion, a PE ratio of 41.62, a price-to-earnings-growth ratio of 2.89 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.93 earnings per share. Analysts predict that Hologic, Inc. will post 4.09 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on HOLX. StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $82.00 target price on shares of Hologic in a report on Friday, August 16th. Evercore ISI increased their price objective on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Leerink Partners lowered their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, Citigroup cut Hologic from a “buy” rating to a “neutral” rating and dropped their target price for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $87.50.

Insider Buying and Selling

In other Hologic news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the transaction, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.75% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.